# Ambrx

Source: https://onco.cc/companies/ambrx/  
OnCo record `ambrx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ambrx is a La Jolla, California biotechnology company founded in 2003 whose HER2 antibody-drug conjugate ARX788 is in OnCo's phase 3 ACE-Breast-02 trial (with Zhejiang Medicine, in China) and the global phase 2 ACE-Breast-03 trial after trastuzumab deruxtecan.

## Summary

Ambrx is an organisation based in La Jolla, United States, founded in 2003 (Wikidata Q100955904, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor. In OnCo it sponsors ACE-Breast-02 (phase 3, with Zhejiang Medicine: ARX788 against lapatinib plus capecitabine in HER2-positive advanced breast cancer after trastuzumab and a taxane, recorded as positive) and NCT04829604 (ACE-Breast-03, phase 2, ARX788 in HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan). ARX788 is its own compound, the basis for the biotech type.

## Fields

- Kind: Company
- Last checked: 2026-09-22
- Also known as: Ambrx, Inc.; Ambrx Inc; Ambrx Biopharma
- Tags: ctgov-sponsor; wave5-sponsor
- HQ: La Jolla, California
- Type: biotech
- Website: http://ambrx.com/

## Sources

- Official website: http://ambrx.com/
- Wikidata Q100955904: https://www.wikidata.org/wiki/Q100955904
- ClinicalTrials.gov: trials led by Ambrx, Inc.: https://clinicaltrials.gov/search?lead=Ambrx%2C%20Inc.

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [ARX788](https://onco.cc/drugs/arx788/)
- trials: [ACE-Breast-02](https://onco.cc/trials/ace-breast-02/), [ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)](https://onco.cc/trials/nct04829604/)

---
JSON: https://onco.cc/api/v1/entities/ambrx.json